Dr. Sophia Cameron discusses how radiation therapy fits into evolving GU cancer care, particularly for symptomatic lesions and oligometastatic prostate cancer. She highlights that external beam radiation remains critical for rapid symptom control, while newer approaches like radioligand therapy require more long-term data. The conversation also explores biomarker use, noting that ctDNA is effective for detecting systemic disease but not reliable for local bladder response, reinforcing the continued need for cystoscopy and additional tools like urine-based assays.
Belzutifan Moves Earlier in Kidney Cancer Care
Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan
